Compound J27 alleviates obesity-induced cardiomyopathy by targeting JNK2

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Obesity is a rising global health issue, contributing significantly to heart failure through obesity-induced cardiomyopathy (OCM).
• Current treatments for OCM are indirect, lacking disease-modifying therapies targeting specific pathological mechanisms.
• J27, a selective inhibitor of c-Jun N-terminal kinase 2 (JNK2), was developed to address these limitations.

Purpose of the Study:

• To investigate the specific role of JNK2 in the development of OCM.
• To evaluate the therapeutic potential of J27 in preclinical models of OCM.
• To explore the molecular mechanisms underlying J27's efficacy.

Main Methods:

• A high-fat diet (HFD) mouse model was used to induce OCM and test J27.
• Cardiac structure and function were assessed via histology, biochemical assays, and echocardiography.
• In vitro studies in cardiomyocytes and macrophages examined J27's effects on injury, calcium handling, and inflammation.

Main Results:

• J27 treatment dose-dependently improved cardiac function, reduced hypertrophy, and attenuated fibrosis in HFD-fed mice.
• J27 normalized cardiomyocyte calcium handling by inhibiting the JNK2/CaMKIIδ pathway, reducing injury.
• J27 suppressed macrophage inflammation via the JNK2/c-Jun pathway, mitigating OCM progression.

Conclusions:

• JNK2 is a key regulator in OCM, influencing both cardiomyocyte calcium balance and inflammatory responses.
• J27 demonstrates significant cardioprotective effects against HFD-induced OCM.
• J27 shows promise as a targeted therapy for obesity-related cardiac dysfunction.